Daiichi Sankyo, Inc. (4568.t) and ArQule, Inc. (ARQL) Enroll First Hepatocellular Carcinoma Patient Into Global Phase 3 Trial for Tivantinib
1/31/2013 10:19:49 AM
TOKYO & WOBURN, Mass.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC (MET-high patients with tivantinib in HCC) trial of tivantinib (ARQ 197). Tivantinib, an investigational selective inhibitor of MET, a receptor tyrosine kinase, is being evaluated for the treatment of patients diagnosed with hepatocellular carcinoma (HCC) who have received one or two prior systemic anti-cancer therapies.
comments powered by